Anna Kopczak, Michael S Stringer, Hilde van den Brink, Danielle Kerkhofs, Gordon W Blair, Maud van Dinther, Laurien Onkenhout, Karolina A Wartolowska, Michael J Thrippleton, Marco Duering, Julie Staals, Martin Middeke, Elisabeth André, Bo Norrving, Marie-Germaine Bousser, Ulrich Mansmann, Peter M Rothwell, Fergus N Doubal, Robert van Oostenbrugge, Geert Jan Biessels, Alastair Js Webb, Joanna M Wardlaw, Martin Dichgans
BACKGROUND: Hypertension is the leading modifiable risk factor for cerebral small vessel diseases (SVDs). Yet, it is unknown whether antihypertensive drug classes differentially affect microvascular function in SVDs. AIMS: To test whether amlodipine has a beneficial effect on microvascular function when compared to either losartan or atenolol, and whether losartan has a beneficial effect when compared to atenolol in patients with symptomatic SVDs. DESIGN: TREAT-SVDs is an investigator-led, prospective, open-label, randomised crossover trial with blinded endpoint assessment (PROBE design) conducted at five study sites across Europe...
March 2023: European Stroke Journal